**Sup Table 1.** Characteristics of patients according to the reason for the initial IFX discontinuation.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **Secondary loss of response****N = 48** | **Intolerance****N = 21** | **p-value** |
| **Male** | N (%) | 20 (42) | 7 (33) | 0.51 |
| **Age** (Years) | Median (IQR) | 34 (26-43) | 35 (28-41) | 0.37 |
| **Smoking**ActivePrevious | N (%)N (%) | 16 (34)13 (28) | 6 (29)3 (14) | 0.30 |
| **Disease duration** (Years) | Median (IQR) | 8.7 (6.6-13.8) | 14.1 (11.8-20.8) | 0.005 |
| **Illness behaviour**B1 (non-stricturing, non penetrating)B2 (stricturing)B3 (penetrating) | N (%)N (%)N (%) | 15 (31)18 (38)14 (29) | 8 (38)10 (48)5 (24) | 0.580.430.65 |
| **CD location**L1 (ileal)L2 (colonic)L3 (ileocolonic)Upper Gastrointestinal Disease | N (%)N (%)N (%)N (%) | 15 (31)10 (21)25 (52)6 (12) | 6 (29)6 (29)11 (52)0 (0) | 0.820.700.980.22 |
| **Perianal lesions** | N (%) | 24 (50) | 13 (62) | 0.36 |
| **History of intestinal resection for CD** | N (%) | 19 (40) | 8 (38) | 0.91 |
| **Family history of IBD** | N (%) | 14 (29) | 6 (29) | 1.00 |
| **Duration between initial discontinuation and IFX restart (Months)** | Median (IQR) | 34.5 (17.2-62.0) | 76.2 (33.1-101.4) | 0.007 |
| **CDAI at inclusion** | Median (IQR) | 263 (226-349) | 244 (175-421) | 0.99 |
| **CRP at inclusion (mg/L)** | Median (IQR) | 14.4 (6.6-31) |  10.2 (5-31) | 0.68 |
| **Fecal calprotectin at inclusion (μg/g)** | Median (IQR) | 1084 (476-1800) | 1190 (106-1573) | 0.68 |
| **Concomitant treatments** Corticosteroids Immunosuppressants | N (%)N (%) | 15 (31)5 (10) | 8 (38)1 (5) | 0.590.66 |